



S. HERNANDEZ ROJAS, M.D.P. DÍAZ RUIZ, J.A. DE LEÓN GIL, M. MIGUELEZ MORALES, M. SUAREZ GONZALEZ, A. ESTÉVEZ LÓPEZ, J. MERINO ALONSO, E. RAMOS SANTANA, J.A. MARTÍN CONDE


Hospital Nuestra Señora de la Candelaria

PURPOSE

To analyze how naive HIV treatment has changed over the years both in economic aspects and in usual clinical practice

MATERIAL AND METHODS

- Longitudinal and descriptive observational study
- January 2013 - September 2018
- Antiretrovirals, only naive patients
- DRAGOAE® and Farmatools® programs
- The main variables under study were: initial antiretroviral treatment, patient cost per year and date of treatment initiation.



RESULTADOS

YEAR	NAIVE PATIENTS	AVERAGE COST/YEAR/PATIENT (€)	TREATMENTS
2013	105	7313.96	FTC/TDF/RPV 31%
2014	180	7441.72	FTC/TDF/RPV 30%
2015	140	7269	ABC/3TC/DLG 23%
2016	146	7201.88	ABC/3TC/DLG 30%
2017	170	6600.62	ABC/3TC/DLG 29%
Jan 2018- Sep 2018	100	5844.35	ABC/3TC/DLG 28%
Total	841	41671.53	

CONCLUSIONES

The integrase inhibitors (DLG and EVG) have become the 3rd drug of choice in the HAART of the naive patient. Moving to IPs and NNRTIs. The combination ABC/DLG/3TC is the most prescribed since 2015, it is the STR most cost effective in Spain. The average cost per patient has decreased 1500€/year on average compared to 2014, this is due to the high use of ABC/DLG/3TC and the current low cost of the combination FTC/TDF